Eterna Therapeutics Inc

$2.29
(as of Jun 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Eterna Therapeutics Inc

Stock Price
$2.29
Ticker Symbol
ERNA
Exchange
NASDAQ

Industry Information for Eterna Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Eterna Therapeutics Inc

Website
https://www.ernexatx.com
Country
USA
Full Time Employees
6

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Fundamentals for Eterna Therapeutics Inc

Market Capitalization
$9,520,858
EBITDA
$-14,075,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-32.70
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
4,157,580
Percent Owned by Insiders
41.91%
Percent Owned by Institutions
1.35%
52-Week High
52-Week Low

Technical Indicators for Eterna Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
29.44
ATR
0.38

Analyst Ratings for Eterna Therapeutics Inc

Strong Buy
Buy
Hold
Sell
Strong Sell

News About Eterna Therapeutics Inc

Jun 11, 2025, 5:11 PM EST
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) is registering 57.05M shares of common stock for resale by selling stockholders. See more.
Jun 11, 2025, 9:35 AM EST
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. See more.
Jun 10, 2025, 2:26 PM EST
(RTTNews) - Ernexa Therapeutics (ERNA), a biotech firm focused on cell therapies for cancer and autoimmune diseases, will implement a 1-for-15 reverse stock split of its common shares, effective June 12, 2025. See more.
Jun 10, 2025, 9:34 AM EST
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) trades -19% as the Co. announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-15 [https://seekingalpha.com/pr/20132017-ernexa-therapeutics-announces-1-forminus-15-reverse-stock-split], effective June 12, 2025. See more.